G&S Capital’s iShares Biotechnology ETF IBB Stock Holding History

G&S Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,544	Closed	-$3.98M	–	100
2022 Q1	$3.98M	Buy	+30,544	New	+$3.98M	2.13%	11
2020 Q2	–	Sell	-42	Closed	-$4K	–	129
2020 Q1	$4K	Buy	+42	New	+$4.84K	0.01%	161

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

G&S Capital's IBB Position: Q2 2022 in Review

G&S Capital sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 30,544 shares — an estimated $3.98M sold.

G&S Capital first reported a position in IBB in Q1 2020 and held it in 2 quarters. The position peaked at $3.98M in Q1 2022. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

G&S Capital reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
G&S Capital sold 30,544 iShares Biotechnology ETF shares in Q2 2022, an estimated $3.98M.
G&S Capital first reported a position in iShares Biotechnology ETF in Q1 2020 and held it in 2 quarters.
G&S Capital's iShares Biotechnology ETF position peaked at $3.98M in Q1 2022.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on G&S Capital's 13F filing for Q2 2022, filed 21 Jul 2022.